Kuanrong Rong , Ziyun Li , Xiaoming Wu , Shan Gao , Jie Zhao , Jing Yang , Xiaorui Jiang , Jing Zhang , Wenjian Tang
{"title":"Natural phenol carbamates: Selective BuChE/FAAH dual inhibitors show neuroprotection in an Alzheimer's disease mouse model","authors":"Kuanrong Rong , Ziyun Li , Xiaoming Wu , Shan Gao , Jie Zhao , Jing Yang , Xiaorui Jiang , Jing Zhang , Wenjian Tang","doi":"10.1016/j.ejmech.2024.117003","DOIUrl":null,"url":null,"abstract":"<div><div>FAAH inhibition can indirectly enhance endocannabinoid signaling to therapeutic levels, effectively preventing or slowing its progression of Alzheimer's disease (AD). Hence, the search for effective dual FAAH/cholinesterase inhibitors is considerable need for disease-modifying therapies. To this aim, we designed, synthesized, and tested three series of natural phenol carbamates. The majority of carbamates proved to be potent on a single target, amongst them, compound <strong>D12</strong> containing paeonol motif was identified as an effective dual BuChE/FAAH inhibitor, with well-balanced nanomolar activity (IC<sub>50</sub> = 81 and 400 nM for <em>h</em>BuChE and <em>h</em>FFAH, respectively). <strong>D12</strong> possessed BBB penetrating ability, benign safety, neuroprotection and pseudo-irreversible BuChE inhibition (<em>K</em><sub>d</sub> = 2.11 μM, <em>k</em><sub>2</sub> = 2.27 min<sup>−1</sup>), showing good drug-like properties. <strong>D12</strong> also modulated the BV2 microglial polarization to inhibit neuroinflammation. <em>In vivo</em> study verified that <strong>D12</strong> improved A<em>β</em><sub>1-41</sub>-induced learning impairments in AD mouse model for both short- and long-term memory responses. Thus, the dual activity of <strong>D12</strong> could lead to a potentially more effective treatment for the counteraction of AD progression.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"281 ","pages":"Article 117003"},"PeriodicalIF":6.0000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0223523424008857","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
FAAH inhibition can indirectly enhance endocannabinoid signaling to therapeutic levels, effectively preventing or slowing its progression of Alzheimer's disease (AD). Hence, the search for effective dual FAAH/cholinesterase inhibitors is considerable need for disease-modifying therapies. To this aim, we designed, synthesized, and tested three series of natural phenol carbamates. The majority of carbamates proved to be potent on a single target, amongst them, compound D12 containing paeonol motif was identified as an effective dual BuChE/FAAH inhibitor, with well-balanced nanomolar activity (IC50 = 81 and 400 nM for hBuChE and hFFAH, respectively). D12 possessed BBB penetrating ability, benign safety, neuroprotection and pseudo-irreversible BuChE inhibition (Kd = 2.11 μM, k2 = 2.27 min−1), showing good drug-like properties. D12 also modulated the BV2 microglial polarization to inhibit neuroinflammation. In vivo study verified that D12 improved Aβ1-41-induced learning impairments in AD mouse model for both short- and long-term memory responses. Thus, the dual activity of D12 could lead to a potentially more effective treatment for the counteraction of AD progression.
期刊介绍:
The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers.
A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.